Literature DB >> 30360887

Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation.

Adam D Niku1, Takahiro Shiota2, Robert J Siegel2, Florian Rader3.   

Abstract

Left atrial appendage (LAA) thrombus in nonvalvular atrial fibrillation or flutter (AF) is a major cause of stroke and presents a therapeutic dilemma in a rhythm-control strategy. The prevalence and resolution of LAA thrombus has not been studied well in the era of non-vitamin K antagonist oral anticoagulant use. This study sought to establish (1) the prevalence of LAA thrombus (2) the prevalence of LAA thrombus despite antithrombotic therapy, (3) the rate of persistence of LAA thrombus despite appropriate anticoagulant prescriptions, and (4) determinants of LAA thrombus persistence. Consecutive transesophageal echocardiograms (TEE) performed in patients with AF were reviewed to estimate the overall prevalence of LAA thrombus and the resolution rate in those with repeat studies. Multivariable logistic regression was used to identify clinical and echocardiographic predictors of thrombus resolution. Of 1,485 patients with AF, 117 (8%) had LAA thrombus. Of those, 62 had repeat TEE within 1 year and 58 (94%) were prescribed adequate anticoagulation in TEE studies (mean interval 96 ± 72 days). Thirty-seven patients (60%) had LAA thrombus resolution. Thrombus resolution rate was only 79% in patients considered on appropriate anticoagulation. Patients with persistent LAA thrombus were more likely to have diabetes; no other clinical or echocardiographic variable was independently associated with thrombus resolution. There was no significant difference in LAA thrombus resolution between non-vitamin K antagonist oral anticoagulants and warfarin. LAA thrombus persistence despite adequate anticoagulation is relatively common and difficult to predict clinically; TEE before electrical cardioversion should be considered regardless of anticoagulation status.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30360887     DOI: 10.1016/j.amjcard.2018.09.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.

Authors:  Yoshiyuki Morishima; Chikako Kamisato; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

2.  Bailout left atrial appendage occluder for pulmonary vein isolation and electrical cardioversion in patients with atrial fibrillation and left atrial appendage thrombus: a pilot study.

Authors:  Chin-Feng Tsai; Pang-Shuo Huang; Fu-Chun Chiu; Jien-Jiun Chen; Sheng-Nan Chang; Jung-Cheng Hsu; Su-Kiat Chua; Hsiao-Liang Cheng; Yi-Chih Wang; Juey-Jen Hwang; Chia-Ti Tsai
Journal:  Clin Res Cardiol       Date:  2022-09-02       Impact factor: 6.138

3.  Imaging of left heart intracardiac thrombus: clinical needs, current imaging, and emerging cardiac magnetic resonance techniques.

Authors:  Peng Chang; Jiayu Xiao; Zhehao Hu; Alan C Kwan; Zhaoyang Fan
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

Review 4.  Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion.

Authors:  Enrico Melillo; Giuseppe Palmiero; Adele Ferro; Paola Elvira Mocavero; Vittorio Monda; Luigi Ascione
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

5.  Early Postoperative Immunothrombosis of Bioprosthetic Mitral Valve and Left Atrium: A Case Report.

Authors:  Alexander Kostyunin; Tatiana Glushkova; Alexander Stasev; Rinat Mukhamadiyarov; Elena Velikanova; Leo Bogdanov; Anna Sinitskaya; Maxim Asanov; Evgeny Ovcharenko; Leonid Barbarash; Anton Kutikhin
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

6.  Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?

Authors:  Anna Michalska; Iwona Gorczyca; Magdalena Chrapek; Agnieszka Kapłon-Cieślicka; Beata Uziębło-Życzkowska; Katarzyna Starzyk; Olga Jelonek; Monika Budnik; Monika Gawałko; Paweł Krzesiński; Agnieszka Jurek; Piotr Scisło; Janusz Kochanowski; Marek Kiliszek; Grzegorz Gielerak; Krzysztof J Filipiak; Grzegorz Opolski; Beata Wożakowska-Kapłon
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.